| HS Code | 176123 |
| Product Name | D-Lysine |
| Chemical Name | (R)-2,6-diaminohexanoic acid |
| Cas Number | 923-27-3 |
| Molecular Formula | C6H14N2O2 |
| Molecular Weight | 146.19 g/mol |
| Appearance | White crystalline powder |
| Purity | ≥98% |
| Melting Point | 218-220 °C (decomposes) |
| Solubility | Soluble in water; slightly soluble in ethanol; insoluble in ether |
| Optical Rotation | -14.6° (c=2, H2O) |
| Pka | 2.18, 8.95, 10.53 |
| Isoelectric Point | 9.74 |
| Storage Condition | Store in a cool, dry, sealed container away from light |
As an accredited D-Lysine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | D-Lysine, 25 g, supplied in a sealed amber glass bottle with tamper-evident cap and desiccant. |
| Container Loading (20′ FCL) | 20′ FCL for D-Lysine: dry powder loaded in drums or bags, secured, container sealed for safe transport. |
| Shipping | D-Lysine is shipped as a stable crystalline powder or aqueous solution. Packaging utilizes sealed, moisture-resistant containers, such as foil-lined bags or HDPE drums, to prevent contamination and caking. Transport requires dry, temperature-controlled conditions, away from incompatible substances, with proper labeling to ensure safe handling and regulatory compliance. |
| Storage | Store D-Lysine in a tightly sealed container in a cool, dry, well-ventilated area away from moisture, direct sunlight, and incompatible materials such as strong oxidizers. Maintain room temperature, avoid excessive heat, and keep the container properly labeled. Under these conditions, the chemical remains stable for its intended shelf life. |
| Shelf Life | Stable for up to two years when stored sealed, cool, and dry, protected from light and moisture. |
Poly-D-lysine hydrobromide derived from D-lysine monohydrochloride is deposited onto tissue-culture-treated polystyrene and glass substrates to create a protease-resistant adhesive interface for primary neurons, stem cells, and serum-free assays. The synthetic route converts the monomer to an N-carboxyanhydride by reacting D-lysine hydrochloride with triphosgene in anhydrous tetrahydrofuran at 40–50 °C; ring-opening polymerization is initiated with 1–2 mol% of a primary amine under a nitrogen sweep, yielding hydrobromide salt with average molecular weights grouped in 70,000–150,000 Da, 150,000–300,000 Da, and >300,000 Da bands. For coating workflows, the polymer is reconstituted in 0.15 M borate buffer at pH 8.5, sterile-filtered through a 0.22 µm membrane, and dispensed into multiwell plates at 0.01–0.1 mg/mL depending on the polymer band. Liquid handling variance remains the dominant production failure mode: edge wells accumulate excess coating due to meniscus pinning during vacuum aspiration, and acceptable plates typically require a well-to-well coefficient of variation below 15 % for total protein fluorescence. Vacuum plasma pretreatment at 100–200 W for 60–120 s increases polystyrene wettability and reduces delamination in long-term culture. The D-configuration resists proteolytic degradation more effectively than poly-L-lysine, which extends the functional lifetime of coated vessels under serum-free and trypsin-containing media. Cytotoxicity acceptance follows ISO 10993-5:2009 and USP <87>; endotoxin is controlled below 0.1 EU/mL. Publication-level comparative data across all coating molecular weights remain limited, but vendor handling specifications converge on the ranges in Table 1.
| Average molecular weight range | Working concentration | Incubation condition | Typical substrate |
|---|---|---|---|
| 70,000–150,000 Da | 0.1 mg/mL | 25 °C, 2 h | Polystyrene multiwell plates |
| 150,000–300,000 Da | 0.05 mg/mL | 37 °C, 1 h | Glass and plastic surfaces |
| >300,000 Da | 0.01–0.05 mg/mL | 25 °C, 18 h | Low-adhesion substrates or semi-adherent cell systems |
During Fmoc-based solid-phase peptide synthesis, D-lysine is introduced as Fmoc-D-Lys(Boc)-OH rather than the free amino acid, because the ε-amino group must remain blocked to prevent branching. Coupling protocols on Rink amide AM resin at 0.1 mmol scale use 3.0 equivalents of protected monomer, 3.0 equivalents of HCTU, and 6.0 equivalents of DIPEA in dimethylformamide. Single coupling at 50 °C for 2–5 min routinely yields Kaiser-negative results; steric hindrance at the α-carbon is not the limiting factor. The critical process conflict occurs when Fmoc-D-Lys(Boc)-OH contains residual free amine or when automated synthesizer delivery lines retain trace water, leading to premature Fmoc loss and double incorporation. The side-chain Boc group is removed with 95 % trifluoroacetic acid, 2.5 % triisopropylsilane, and 2.5 % water; incomplete acidolysis leaves a +100 Da adduct detectable by UPLC-MS. Cleavage vessels with jacket control at 20 ± 2 °C reduce thermal degradation of acid-sensitive amide bonds. For sequences requiring orthogonally addressable side chains, Fmoc-D-Lys(ivDde)-OH and Fmoc-D-Lys(Mtt)-OH are substituted according to Table 2.
| Protected derivative | Side-chain group | Removal conditions | Application mode |
|---|---|---|---|
| Fmoc-D-Lys(Boc)-OH | Boc | 95 % TFA / 2.5 % TIS / 2.5 % H2O | Standard linear peptide sequences |
| Fmoc-D-Lys(ivDde)-OH | ivDde | 2 % hydrazine in DMF | Orthogonally addressable side-chain branching |
| Fmoc-D-Lys(Mtt)-OH | Mtt | 1 % TFA in DCM, repeated | Selective on-resin side-chain deprotection |
| Boc-D-Lys(Z)-OH | Z | HF or catalytic hydrogenation | Boc-based SPPS protocols |
Racemic carboxylic acid intermediates are resolved by D-lysine base through diastereomeric salt crystallization in methanol or aqueous methanol. A racemic acid stream at 1.0 M is heated to 50–60 °C, charged with 0.5–1.0 molar equivalent of D-lysine, and cooled under seeded nucleation. The less soluble diastereomeric D-lysine salt crystallizes as plate-like particles; the antipodal acid remains in the mother liquor. Cooling at 0.1–0.3 K/min from 55 °C to 2–5 °C avoids oiling-out and uncontrolled primary nucleation. The crystal slurry is filtered through a Nutsche filter equipped with 0.45 µm polypropylene cloth and reslurried in cold isopropanol at <0 °C to strip adsorbed mother liquor. The operational boundary is strict: D-lysine lots containing >0.5 % L-lysine by area normalization on chiral HPLC collapse the separation factor and require repurification by recrystallization from water/ethanol. Batch-to-batch crystal habit is monitored by focused-beam reflectance measurement; a chord length distribution shift below 10 µm indicates excessive secondary nucleation and downstream filter fouling. The equipment train typically includes a controlled crystallization reactor with overhead agitation at 90–120 rpm, a temperature ramping system, and an inert nitrogen overlay to prevent carbonate salt formation. The supernatant is assayed by chiral HPLC using USP <621> system suitability criteria. Published data for this specific configuration is limited; the described conditions are baseline ranges derived from general diastereomeric salt resolution methodology.
For chiral purity release testing of L-lysine hydrochloride fermentation lots, D-lysine hydrochloride with certified enantiomeric excess above 99.5 % is used as an external reference standard to assign retention time and resolution. The ligand-exchange HPLC format employs a chiral crown ether stationary phase, mobile phase at pH 1.5–2.0 aqueous perchloric acid, column temperature 5–10 °C, and UV detection at 200–210 nm. Resolution between D- and L-lysine must exceed 1.5 before lot release. Feed-grade amino acid monographs typically set the D-lysine content below 1.0 % relative to total lysine; pharmaceutical-grade material may be specified below 0.1 %. Injection of a 0.1 % (w/v) D-lysine standard solution bracketing the sample sequence corrects integration drift and retention time shifts caused by perchloric acid mobile phase viscosity changes. Because the hydrochloride salt is hygroscopic, the standard is oven-dried at 105 °C to constant mass and stored over phosphorus pentoxide in a desiccator. Accepted chromatographs require a relative standard deviation below 2.0 % across six replicate injections and a tailing factor between 0.8 and 1.5. The method is appropriate for raw material and batch record documentation under USP <621>.
Enzymatic assay systems for D-amino acid oxidase activity use D-lysine hydrochloride as a low-turnover substrate to verify method sensitivity without saturating the chromogenic oxygen acceptor. Reactions are prepared in 100 mM sodium phosphate at pH 8.0; the oxidation product is coupled to horseradish peroxidase and a colorimetric acceptor monitored at 410 nm. A D-lysine standard curve from 0.05–2.0 mM brackets the expected activity range. Because D-lysine turnover is lower than D-alanine, the substrate is useful for selectivity assessments when samples contain substantial L-lysine background. Interfering catalase in biological matrices is inactivated by heating at 56 °C for 30 min or by adding sodium azide at 0.02 % (w/v). The operational boundary is narrow: molecular oxygen depletion in sealed microplates produces rate non-linearity above 10 min; kinetic reads should therefore be acquired continuously during the first 5 min. Published data for this specific configuration is limited; the stated ranges follow general oxidase assay methodology.
Competitive D-Lysine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
As the (2R)-enantiomer of 2,6-diaminohexanoic acid, D-lysine is supplied as the crystalline free base (CAS 923-27-3, molecular formula C6H14N2O2, molar mass 146.19 g/mol) and as the monohydrochloride salt (CAS 7274-88-6, molar mass 182.65 g/mol). Two product code families encode counterion and purity tier: D-Lys-OH-99 for free base with release assay ≥99.0% and D-Lys-HCl-98 for hydrochloride with release assay ≥98.5%. Both forms are white crystalline powders that are freely soluble in water and dilute mineral acids. The free base yields an alkaline aqueous solution, whereas the hydrochloride provides an acidic solution. The substance is used as a synthetic chiral building block and analytical chiral standard; it is not listed in FDA 21 CFR 172.320 as a direct nutrient supplement, whereas L-lysine monohydrochloride is listed.
At 25 °C in water, the lysine carboxylate pKa is 2.20, the α-amino pKa is 8.90, and the ε-amino pKa is 10.28. These constants govern salt selection for formulation and derivatization pH control.
For chiral purity control, the separation of D-lysine from L-lysine is performed by chiral HPLC. A crown-ether chiral stationary phase, e.g., CROWNPAK CR-I(+) 150 × 3.0 mm, 5 µm, is operated with aqueous perchloric acid at pH 1.8–2.2, flow rate 0.4 mL/min, column temperature 25 °C, and UV detection at 210 nm. System suitability requires resolution ≥1.5 between the D and L peaks and tailing factor ≤1.5 per USP <621>. Release for peptide-grade D-lysine hydrochloride permits ≤0.3% L-lysine by area normalization; the limit is tightened from ≤0.5% when the product is used for solid-phase synthesis of pharmaceutical peptides because epimeric impurities co-elute with the target peptide in preparative reversed-phase chromatography. Published data for this specific configuration is limited; method equivalency should be demonstrated per ICH Q2(R1) before replacing the supplier method in a validated process.
Production-quality control commonly uses an HPLC system with a diode-array detector calibrated with two-point bracketing standards of D-lysine and L-lysine at 0.1 mg/mL and 1.0 mg/mL. The limit of quantification for L-lysine is 0.05% by area at a signal-to-noise ratio of 10:1 per ICH Q2(R1). Sample preparation for chiral HPLC uses aqueous hydrochloric acid at pH 1.8 to protonate both amino groups and suppress peak tailing. Injection volume is 5 µL, and run time is 20 min. Retention times are approximately 12.5 min for L-lysine and 14.2 min for D-lysine on the crown-ether column; these values are equipment-dependent and require system suitability verification.
| Parameter | Release limit | Method/standard |
|---|---|---|
| Appearance | White or almost white crystalline powder | Visual |
| Specific optical rotation [α]D20 (c=1, 1 M HCl) | -19.5° to -21.5° | Ph. Eur. 2.2.7 / USP <781> |
| Assay (anhydrous basis) | 98.5–101.0% | Ph. Eur. 2.2.20 potentiometric titration |
| Chloride | 19.2–19.7% | Ph. Eur. 2.2.20 |
| L-Lysine | ≤0.3% | Chiral HPLC / USP <621> |
| Loss on drying | ≤0.5% | USP <731> vacuum 60 °C |
| Residue on ignition | ≤0.1% | USP <281> |
| Lead | ≤5 ppm | ICP-MS / EPA 6020 |
In solid-phase peptide synthesis, the free base is not used directly; the orthogonally protected derivative Fmoc-D-Lys(Boc)-OH (CAS 143824-78-6) is the standard reaction input. The ε-Boc group is removed with concentrated trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v) during global deprotection. Fmoc removal uses 20% piperidine in N,N-dimethylformamide. An automated microwave peptide synthesizer, e.g., CEM Liberty Blue, is operated with 0.5 M N,N′-diisopropylcarbodiimide and 0.5 M ethyl cyanohydroxyiminoacetate in N,N-dimethylformamide at 75 °C for 2 min per coupling cycle. Preparative purification uses a C18 column 250 × 21.2 mm, 5 µm, eluent A 0.1% trifluoroacetic acid in water, eluent B acetonitrile, gradient 10–40% B over 30 min, flow rate 15 mL/min, and detection at 214 nm.
D-Lysine is acylated at the ε-amino group before Fmoc protection. In a 50 L jacketed glass reactor, di-tert-butyl dicarbonate is added to a slurry of D-lysine in water/1,4-dioxane at pH 10.5 maintained with 2 M sodium hydroxide. The reaction temperature is held at 20–25 °C by jacket cooling because the Boc protection is exothermic. When the pH falls below 10.0, residual unreacted D-lysine increases and subsequent Fmoc protection becomes sluggish. This batch-to-batch pH excursion is documented as a manufacturing bottleneck and is controlled by pH-stat addition of base rather than manual liquid dosing.
Because mammalian amino acid transporters recognize the L-configuration, D-lysine differs from L-lysine monohydrochloride in transport and metabolic fate. In standard lysine decarboxylase media, L-lysine monohydrochloride is decarboxylated to cadaverine at 37 °C within 24 h, whereas D-lysine does not serve as a substrate for lysine decarboxylase (EC 4.1.1.18) under identical pH and inoculum conditions. This stereospecificity forms the basis of D-lysine use as a negative control in microbiological lysine assays.
| Property | D-Lysine monohydrochloride | L-Lysine monohydrochloride | DL-Lysine |
|---|---|---|---|
| CAS | 7274-88-6 | 657-27-2 | 70-53-1 |
| Specific rotation [α]D20 (c=1, 1 M HCl) | -20.5° | +20.5° | 0.0° |
| Nutritional availability | Not metabolized as a lysine source in mammals | Essential amino acid nutrient; listed in FDA 21 CFR 172.320 | Half of the dose is unavailable due to the D-isomer |
| Synthetic role | Chiral building block for D-peptides and antibiotic analogs | Feed/food supplement and peptide synthesis standard | Resolution studies; racemic method-development standard |
| Analytical marker | Negative control in L-lysine uptake and decarboxylase assays | Calibrator for L-lysine assays | System-suitability racemate for chiral methods |
When the hydrochloride is replaced by the free base in an aqueous formulation, the pH shifts from approximately 5.2 to above 10. This shift affects buffer capacity and the solubility of pH-sensitive excipients. Lyophilization process design must be re-qualified after such a substitution because the collapse temperature depends on the ionized form. A lyophilizer with shelf temperature ramped from -40 °C to 25 °C at 0.5 °C/min under chamber pressure 0.05 mbar may be used; published data for this specific configuration is limited. The hydrochloride contributes 35.45 g/mol chloride per formula unit and increases osmolality by approximately 1 mOsm/kg for each 1 mM increase in chloride concentration.
For storage, tightly closed containers under dry nitrogen at 2–8 °C are applied. Moisture uptake above 60% relative humidity leads to caking and loss of assay traceability of the free base. The substance is incompatible with strong oxidizing agents, nitrosating conditions, and reducing sugars under alkaline aqueous storage because of Maillard degradation. For solid-phase peptide synthesis, residual water above 0.3% in the Fmoc-D-Lys(Boc)-OH derivative reduces active-ester coupling efficiency; drying under vacuum at 25 °C for 12 h is applied before use.